StreetInsider.com News Articles

10X Genomics (TXG) Reiterated at Buy by Stifel as MuSpAn Bioinformatics Package Launches

Tue, 08 Sep 2026 07:00:59 -0400

Stifel analyst Daniel Arias reiterated a Buy rating on 10X Genomics (NASDAQ: TXG).

The analyst commented, "The next leg of adoption for spatial biology approaches will no doubt be enabled by new platform offerings, with 10x Genomic's (TXG, $62.65, Buy) about-to-be-commercialized Atera instrument at the center of the conversation on market expansion. In addition to new hardware capabilities, however, software advances that allow for better annotation, integration, and visualization will also be needed. A recent piece in Nature Communications (open access) from a team at the University of Oxford details the introduction of MuSpAn - a bioinformatics package that "unifies over

RBC Capital Starts 10X Genomics (TXG) at Sector Perform

Tue, 01 Sep 2026 02:13:28 -0400

RBC Capital analyst Dan Leonard initiates coverage on 10X Genomics (NASDAQ: TXG) with a Sector Perform rating and a price target of $70.00.

The analyst comments: “We are initiating coverage of 10x Genomics (TXG) with a $70 price target and Sector Perform rating, which reflects a constructive view on the Atera launch and spatial opportunity balanced against a mature single-cell franchise. We could become more constructive on evidence that 10x's single cell franchise (2/3 of product sales) could return to meaningful growth.

10x is the leader in high-plex spatial molecular profiling (>60% share), enabling researchers to map gene and protein expression within

RBC Capital Starts 10X Genomics (TXG) at Sector Perform

Tue, 01 Sep 2026 02:13:28 -0400

RBC Capital analyst Dan Leonard initiates coverage on 10X Genomics (NASDAQ: TXG) with a Sector Perform rating and a price target of $70.00.

10x is the leader in high-plex spatial molecular profiling (>60% share), enabling researchers to map gene and protein expression within

Form 4 10x Genomics, Inc. For: Aug 26 Filed by: Saxonov Serge

Fri, 28 Aug 2026 19:22:00 -0400

si-local-file:///var/storage/secattach/20260828/26999360.html

Form 4 10x Genomics, Inc. For: Aug 26 Filed by: Saxonov Serge

Fri, 28 Aug 2026 19:22:00 -0400

si-local-file:///var/storage/secattach/20260828/26999360.html

Jury finds Parse Biosciences willfully infringed 10x Genomics patents

Fri, 28 Aug 2026 14:41:07 -0400

A federal jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, which was acquired by 10x Genomics (NASDAQ: TXG) in 2025. The jury also upheld the validity of all three patents, rejecting Parse's invalidity challenges.

The jury awarded 10x Genomics more than $4.8 million in damages covering sales of Parse's Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The award is based on a 14% royalty rate applied to infringing Parse sales. The patents at issue are

Jury finds Parse Biosciences willfully infringed 10x Genomics patents

Fri, 28 Aug 2026 14:41:07 -0400

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences